Paper41226558
Acalabrutinib May Offer a New Therapeutic Approach for Consolidation and Maintenance of Primary CNS Lymphoma with Expression of MYD88 and CD79B Gene Variants: A Case Report and Literature Review of Primary CNS Lymphoma in the BTKi Era.
Allison E and 3 others. Int J Mol Sci, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Acalabrutinib May Offer a New Therapeutic Approach for Consolidation and Maintenance of Primary CNS Lymphoma with Expression of MYD88 and CD79B Gene Variants: A Case Report and Literature Review of Primary CNS Lymphoma in the BTKi Era. Papers, record 41226558. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41226558
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Acalabrutinib May Offer a New Therapeutic Approach for Consolidation and Maintenance of Primary CNS Lymphoma with Expression of MYD88 and CD79B Gene Variants: A Case Report and Literature Review of Primary CNS Lymphoma in the BTKi Era.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| CD79 Antigens | Major topic |
| Central Nervous System Neoplasms | Major topic |
| Pyrazines | Major topic |
| Myeloid Differentiation Factor 88 | Major topic |
| Benzamides | Major topic |
| Lymphoma | Major topic |
| Humans | |
| Male | |
| Agammaglobulinaemia Tyrosine Kinase | |
| Middle Aged |
Source PubMed
References84
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39575767 | Distinct epigenetic and transcriptional profiles of Epstein-Barr virus-positive and negative primary CNS lymphomas. | Neuro Oncol | 2025 | https://conductscience.org/library/papers/39575767 | PubMed |
| 2 | 34277452 | Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis. | Front Oncol | 2021 | https://conductscience.org/library/papers/34277452 | PubMed |
| 3 | 31790142 | The immune landscape and response to immune checkpoint blockade therapy in lymphoma. | Blood | 2020 | https://conductscience.org/library/papers/31790142 | PubMed |
| 4 | 38589905 | Ibrutinib disrupts blood-tumor barrier integrity and prolongs survival in rodent glioma model. | Acta Neuropathol Commun | 2024 | https://conductscience.org/library/papers/38589905 | PubMed |
| 5 | 34523186 | Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma. | Cancer Sci | 2021 | https://conductscience.org/library/papers/34523186 | PubMed |
| 6 | 27132696 | Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. | Lancet Haematol | 2016 | https://conductscience.org/library/papers/27132696 | PubMed |
| 7 | 37397356 | CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap. | Front Oncol | 2023 | https://conductscience.org/library/papers/37397356 | PubMed |
| 8 | 36465385 | Bruton's tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review. | Front Oncol | 2022 | https://conductscience.org/library/papers/36465385 | PubMed |
| 9 | 35004280 | Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series. | Front Oncol | 2021 | https://conductscience.org/library/papers/35004280 | PubMed |
| 10 | 35732829 | The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. | Leukemia | 2022 | https://conductscience.org/library/papers/35732829 | PubMed |
| 11 | 30033836 | Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma. | Leuk Lymphoma | 2019 | https://conductscience.org/library/papers/30033836 | PubMed |
| 12 | 30885253 | Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis. | Acta Neuropathol Commun | 2019 | https://conductscience.org/library/papers/30885253 | PubMed |
| 13 | 19767089 | High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. | Lancet | 2009 | https://conductscience.org/library/papers/19767089 | PubMed |
| 14 | 29054815 | Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. | Lancet Haematol | 2017 | https://conductscience.org/library/papers/29054815 | PubMed |
| 15 | 35732356 | Durable remission with Bruton's tyrosine kinase inhibitor therapy in a patient with leptomeningeal disease secondary to relapsed mantle cell lymphoma. | BMJ Case Rep | 2022 | https://conductscience.org/library/papers/35732356 | PubMed |
| 16 | 39866943 | Central nervous system posttransplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation successfully treated with combination therapy of acalabrutinib and immunochemotherapy: A case report and literature review. | EJHaem | 2025 | https://conductscience.org/library/papers/39866943 | PubMed |
| 17 | 38406527 | Complete response of mantle cell lymphoma with central nervous system involvement at diagnosis with acalabrutinib - Case report. | EJHaem | 2024 | https://conductscience.org/library/papers/38406527 | PubMed |
| 18 | 35116520 | Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution. | Transl Cancer Res | 2021 | https://conductscience.org/library/papers/35116520 | PubMed |
| 19 | 38135609 | Evidence-based management of primary and secondary CNS lymphoma. | Semin Hematol | 2023 | https://conductscience.org/library/papers/38135609 | PubMed |
| 20 | 29476222 | Ibrutinib brain distribution: a preclinical study. | Cancer Chemother Pharmacol | 2018 | https://conductscience.org/library/papers/29476222 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42440393 | Rare CNS manifestation of high-risk CLL with excellent response to triplet targeted therapy. | Leuk Res Rep | 2026 | https://conductscience.org/library/papers/42440393 | PubMed |
| 42027642 | Intravascular large B-cell lymphoma mimicking an orbital mass lesion and bilateral cavernous sinus syndrome: A case report. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42027642 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BTK | 695 | PubTator's text mining | https://conductscience.org/library/genes/695 | NCBI Gene |
| CD79B | 974 | PubTator's text mining | https://conductscience.org/library/genes/974 | NCBI Gene |
| MYD88 | 4615 | PubTator's text mining | https://conductscience.org/library/genes/4615 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41226558
GET https://conductscience.org/api/papers/v1/41226558/references?page=2